Clovis Oncology Stock News

Here's what you need to know about trading penny stocks on March 31st The post Trading Penny Stocks? Top Stock Market News for March 31st, 2022 appeared first on Penny Stocks to Buy, Picks, News and I

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx Says FDA Committee Casts Negative Vote On ALS Drug Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Clovis Oncology (CLVS) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial. The post Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today

Clovis Oncology Inc (NASDAQ: CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as first-line maintenance treatment in ovarian cancer

Here's what you need to know about trading penny stocks on March 31st The post Trading Penny Stocks? Top Stock Market News for March 31st, 2022 appeared first on Penny Stocks to Buy, Picks, News and I

Clovis Oncology Inc (NASDAQ: CLVS) is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly impr

Shares of Clovis Oncology Inc. CLVS, -3.51% soared 40.0% in premarket trading on Thursday after the company said its drug, Rubraca, improved survival when used as a maintenance treatment for women wit

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

Which penny stocks are on your watchlist for next week? The post Hot Penny Stocks to Watch Next Week?

During the last session, Clovis Oncology Inc. (NASDAQ:CLVS)’s traded shares were 4.05 million, with the beta value of the company hitting 1.71. At the end of the trading day, the stock’s price was $1.74, reflecting an intraday gain of 10.83% or $0.17. The 52-week high for the CLVS share is $8.95, that puts it down … Will Clovis Oncology Inc. (NASDAQ: CLVS) Stock Boom Or Bust From Here? Read More »

In last trading session, Clovis Oncology Inc. (NASDAQ:CLVS) saw 7.26 million shares changing hands with its beta currently measuring 1.73. Company’s recent per share price level of $1.96 trading at $0.34 or 20.99% at ring of the bell on the day assigns it a market valuation of $260.76M. That closing price of CLVS’s stock is … Clovis Oncology Inc. (NASDAQ:CLVS) Shares Surged 2.08% In A Week – But Can It Maintain Its Gains? Read More »

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.